Brush Biopsy Could Rewrite Mouth Cancer Triage in Primary and Specialist Care
A brush biopsy for mouth cancer is being positioned as a practical alternative to the scalpel biopsy pathway that has dominated oral cancer diagnosis for decades. Researchers at Queen Mary University London say the test could replace more than 90% of painful scalpel biopsies, while delivering a result in under one hour. In a validation study spanning more than 1,000 samples, the brush test distinguished mouth cancer from common potentially malignant disorders with 95.5% overall accuracy.
The result matters because the current diagnostic pathway is blunt. Suspicious oral lesions are often sent for invasive tissue sampling even when the probability of malignancy is low, exposing patients to discomfort, infection risk, and in some cases injury to underlying bone. In a disease where survival depends heavily on early detection, a faster and less traumatic triage tool could change how dentists and oral cancer specialists decide who truly needs a scalpel.
Oral cancer is rising quickly, and the clinical pressure is visible in the referral pathway. A decade-long audit of mouth cancer referrals found a 450% increase in referrals alongside a 50% drop in cancer detection rate. Later audits showed that 92.5% to 99.5% of referred patients did not have cancer, and between 96% and 98% were still cancer free at five-year follow-up. Those numbers point to a system that is working hard but inefficiently, pushing large numbers of patients through invasive workups for lesions that never declare themselves as cancer.
One sentence captures the practical value of the new test: it may allow clinicians to separate risk from noise much earlier.
Why the Brush Test Appeals to Oral Cancer Clinicians
Professor Muy-Teck Teh, a molecular oral oncology specialist at QMUL, described the current pathway as too coarse for the clinical question at hand. Oral cancer is heavily time-dependent: the earlier it is found, the better the chance of successful treatment and survival. A non-invasive brush test fits that logic because it can be repeated, used frequently, and applied to lesions that remain suspicious but not yet definitive.
The test’s strongest advantage is not only accuracy, but accessibility. A result that can be generated rapidly and inexpensively changes the rhythm of care. Rather than moving every uncertain lesion straight to invasive sampling, clinicians could use the brush test as a molecular filter, reserving scalpel biopsy for cases that truly need histology. That would reduce unnecessary procedures while also creating room for serial monitoring of persistent premalignant lesions, especially in high-risk patients who need close surveillance over time.
This is where the biology and the workflow meet. Oral cancers often arise in tissue fields that have already developed visible changes, yet not every abnormal patch represents invasive disease. A repeatable molecular tool offers a way to watch those lesions more intelligently, looking for the shift from benign change to malignant transformation before the disease advances beyond a curable stage.
Accuracy, Validation, and the Clinical Trade-Off
The validation cohort included more than 1,000 samples, and the brush test performed comparably to microbiopsies. In practical terms, that means the device was not simply detecting obvious cancers; it was separating mouth cancer from the kinds of potentially malignant disorders that commonly trigger clinical uncertainty. The 95.5% overall accuracy is striking because it suggests the technology may be able to function as a real triage tool rather than a screening novelty.
Still, the endpoint that matters in everyday practice is not just whether the test can classify samples in a study environment. Dentists and oral medicine teams need to know whether it can reduce false reassurance, avoid missed cancers, and hold up across the messy range of lesions seen in routine clinics. The present data point to strong diagnostic potential, but widespread adoption will depend on how the test performs when applied to diverse patient populations and a broader range of oral pathology.
The case for adoption is strengthened by the harm attached to the standard biopsy route. Scalpel biopsy remains clinically definitive, but it is more than a technical step. It carries pain, anxiety, procedural risk, and sometimes the need for more complex wound management. A brush-based approach could spare many patients from that sequence, particularly when the lesion is suspicious enough to justify molecular triage but not so clearly malignant that immediate excision is unavoidable.
A non-invasive test that can be completed in under an hour alters the entire appointment.
What the Test Could Change for High-Risk Patients
The most immediate use case is surveillance of persistent lesions in people at elevated risk. The research team has argued that the brush biopsy could be used regularly and systematically, allowing clinicians to keep watch on lesions that would otherwise be reviewed intermittently or sent for repeat invasive sampling. In oral cancer care, that distinction is important because time lost to uncertainty can allow a lesion to evolve unnoticed.
High-risk groups stand to gain most if the test is adopted into routine pathways. Patients with persistent white patches, red patches, or other suspicious oral mucosal changes often cycle through observation, referral, and biopsy without a clear answer. A faster molecular readout could reduce over-referral while also making follow-up more disciplined. In a system where most referrals do not result in a cancer diagnosis, a reliable triage test could relieve pressure on specialist services and focus resources where cancer is more likely to be present.
The commercial pathway remains the next hurdle. QMUL is seeking a partner to develop the test for clinical use, and the team believes it could be in use within two years once that step is secured. Until then, the evidence sits at an important threshold: promising enough to challenge current biopsy habits, but still dependent on product development, implementation planning, and confirmation in real-world oral cancer pathways.
Rising Mouth Cancer Rates Give the Test Added Urgency
The backdrop is hard to ignore. Mouth cancer cases in England reached record levels in October 2025, with diagnoses up 37% over the past decade to 9,293 annually. Deaths have risen by 42% over the same period. Those figures sharpen the stakes of any tool that can move diagnosis earlier, reduce unnecessary procedures, or improve triage efficiency.
Oral cancer remains a disease where clinical delay carries a high cost. By the time symptoms become obvious, the biological window for easy treatment may already be narrowing. A brush biopsy that can be done quickly, repeated safely, and read out rapidly offers a plausible way to reduce that delay. The next question is not whether the technology can classify tissue in a laboratory setting, but whether it can be integrated into dental practice without losing the accuracy that made it attractive in the first place.